α-2干扰素与顺铂联合应用的I期研究。
Phase I study of the combination of alpha-2 interferon and cisplatinum.
作者信息
Walsh C, Speyer J L, Wernz J, Hochster H, Grossberg H, Chachoua A, Molinaro P, Meyers M, Blum R H
机构信息
Kaplan Cancer Center, New York University Medical Center, New York 10016.
出版信息
J Biol Response Mod. 1989 Feb;8(1):11-5.
Based on preclinical evidence of synergy, we performed a Phase I study of the combination of alpha-2 interferon and cisplatinum in patients with advanced malignancy. A fixed dose of 5 x 10(6) U/m2 alpha interferon was given three times weekly. Cisplatinum was given once weekly at dose levels of 5, 10, 20, 25, and 30 mg/m2. Dose-limiting toxicity consisted of flu-like symptoms and malaise leading to decreased performance status. Response was seen in a patient with metastatic melanoma. Recommended doses for Phase II study are 5 x 10(6) U/m2 of alpha-2 interferon three times weekly and 25 mg/m2 of cisplatinum once weekly.
基于协同作用的临床前证据，我们对晚期恶性肿瘤患者进行了α-2干扰素与顺铂联合应用的I期研究。每周三次给予固定剂量5×10⁶U/m²的α干扰素。顺铂每周一次，剂量水平分别为5、10、20、25和30mg/m²。剂量限制性毒性包括类流感症状和不适，导致身体状况下降。在一名转移性黑色素瘤患者中观察到了反应。II期研究的推荐剂量为每周三次5×10⁶U/m²的α-2干扰素和每周一次25mg/m²的顺铂。
Zotero 插件